Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

Fundación Lindavista del Corazón AC

Status and phase: Terminated; Phase 3

Conditions: Hypertension

Treatments: Drug: valsartan; Drug: pravastatin; Drug: ezetimibe (+) simvastatin; Drug: simvastatin

Study type: Interventional

Funder types: Other

Identifiers

NCT00738972

MK-0653A-168

2008_020

Details and patient eligibility

About

Evaluate pleiotropic effects of simvastatin in hypertensive patients.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Females Or Males Over 18 Years Old
• Patients With Systemic Arterial Hypertension Grade I And II According With The European Society Of Cardiology
• Left Ventricular hypertrophy Demonstrated By Echocardiography
• Mild To Moderated hypercholesterolemia
• Willing To Participate And Sign The Informed Consent Form (ICF)

Exclusion criteria

• Type 1 Or 2 Diabetes Mellitus
• Familiar hypercholesterolemia
• Low Density Lipoprotein-Cholesterol (LDL-C) > 190 mg/dl
• History Of Myocardial Infarction Or Stable Chronic Angina
• Triglycerides >250 mg/dl

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

12 participants in 4 patient groups

Valsartan 80 mg + Paravastin 40 mg

Active Comparator group

Description:

Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)

Treatment:

Drug: pravastatin

Drug: valsartan

Valsartan 80 mg + Simvastatin 40 mg

Active Comparator group

Description:

Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)

Treatment:

Drug: simvastatin

Drug: valsartan

Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg

Experimental group

Description:

Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)

Treatment:

Drug: ezetimibe (+) simvastatin

Drug: valsartan

Valsartan 80 mg

Active Comparator group

Description:

Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)

Treatment:

Drug: valsartan